RCS - Ondine Biomedical - Steriwave now available through NHS Supply Chain

Ondine BiomedicalAnnouncement

21/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240621:nRSU3020Ta&default-theme=true

RNS Number : 3020T  Ondine Biomedical Inc.  21 June 2024

Non-regulatory announcement

 

ONDINE BIOMEDICAL INC.

 

("Ondine Biomedical", "Ondine", or the "Company")

 

Steriwave now available through NHS Supply Chain

 

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company
pioneering light-activated antimicrobial treatments, is pleased to announce
that its Steriwave(®) nasal photodisinfection is now available through the
NHS Supply Chain, making it significantly easier for NHS hospitals in England
and Wales to purchase. This marks the first time a light-activated
antimicrobial has been available through the NHS Supply Chain, a national body
which manages the sourcing, delivery and supply of healthcare products to the
NHS and healthcare organizations in England and Wales.

 

Steriwave is a groundbreaking antimicrobial treatment that rapidly eliminates
infection-causing pathogens without generating antimicrobial resistance (AMR).
This innovative solution replaces the traditional antibiotic mupirocin, which
is commonly used to decolonize the nose and help prevent healthcare-associated
infections (HAIs) but has high rates of AMR and low patient compliance.

 

In March 2024, Mid Yorkshire Teaching NHS Trust became the first in the UK to
commercially adopt Steriwave as the standard of care for hip and knee surgery
patients to prevent surgical site infections (SSIs). As previously announced,
the commercial adoption of Steriwave at Pontefract and Pinderfields NHS
Hospitals followed a successful initial deployment at Pontefract Hospital.

 

Dr. Stuart Bond, Consultant Antimicrobial Pharmacist and Director of
Innovation at Mid Yorkshire Teaching NHS Trust, commented:

 

"We are very pleased to be the first NHS Trust to give patients access to this
important new technology. SSIs can have a devastating effect on patients and
their families, and we are pleased that we have demonstrated the feasibility
of using Steriwave in our Orthopaedic Centre of Excellence at Pontefract
Hospital. It is a real step forward to making Steriwave more widely available
across the Trust."

 

Ondine is also collaborating with Mid Yorkshire Teaching NHS Trust and Health
Innovation Yorkshire & Humber to sponsor a health economic analysis with
the York Health Economics Consortium (YHEC). The findings of this study,
expected later this year, will be used to support further adoption of
Steriwave across the NHS and additional surgical applications.

 

SSIs, among the most common HAIs, affect one in 20 NHS surgical patients 1 
and cost NHS England over £2 billion annually, 2  with costs expected to rise
due to increasing AMR. WHO and NICE recommend eliminating harmful pathogens
from the nasal cavities before surgery as a key approach to preventing SSIs.
Steriwave uses a proprietary photosensitive microbial stain and activating red
light to destroy nasal pathogens in a single, five-minute treatment without
triggering AMR. As previously announced, Steriwave has been demonstrated in
peer-reviewed studies and over 150,000 treatments to significantly reduce
post-surgical infection rates with no serious adverse events reported,
improving patient outcomes, reducing antibiotic use, and saving millions
annually.

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                           +001 (604) 665 0555

 Singer Capital Markets

(Nominated Adviser and Joint Broker)
 Aubrey Powell, Sam Butcher, Jalini Kalaravy  +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard             +44 (0)77 1000 5910

Enquiries:

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a clinical Canadian life sciences company and leader
in light-activated antimicrobial therapies (also known as
'photodisinfection'). Ondine has a pipeline of investigational products, based
on its proprietary photodisinfection technology, in various stages of
development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe, the UK-CA
mark, and is approved in Canada and several other countries under the name
Steriwave®. In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

About Steriwave(®)

 

Ondine's Steriwave nasal photodisinfection system is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
bacteria, viruses, and fungi colonizing the nose. The photodisinfection
treatment is carried out by a trained healthcare professional and is an
easy-to-use, painless, two-step process. The photosensitizer is applied to
each nostril using a nasal swab, followed by illumination of the area with a
specific wavelength of red laser light for less than five minutes. The light
activates the photosensitizer, causing an oxidative burst that is lethal to
all types of pathogens without causing long-term adverse effects on the nasal
microbiome. A key benefit of this approach-unlike with antibiotics, which have
resistance rates reported as high as 81% 3 -is that pathogens do not develop
resistance to the therapy.

 

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections, 4  and the Society for Healthcare
Epidemiology of America (SHEA) guidelines, published in May 2023, recommend
nasal decolonization for major surgical procedures. 5 

 

 

 

 1  National Institute for Health and Care Excellence, Surgical site
infections: prevention and treatment NICE guideline  NG125 , 2019. (link
(https://www.nice.org.uk/guidance/ng125/chapter/Context) )

 2  Guest JF, Keating T, Gould D, et al Modelling the annual NHS costs
and outcomes attributable to healthcare-associated infections in England BMJ
Open 2020; 10:e033367. (link (https://doi.org/10.1136/bmjopen-2019-033367) )

 3  Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015;70(10):2681-2692. (link
(https://academic.oup.com/jac/article/70/10/2681/829798?login=false) )

 4  Surgical Site Infection Prevention: Key facts on decolonization of nasal
carriers of Staphylococcus aureus. World Health Organization. (link
(https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2)
)

 5  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent
surgical site infections in acute-care hospitals: 2022 Update. Infect Control
Hosp Epidemiol. 2023;44(5):695-720. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/strategies-to-prevent-surgical-site-infections-in-acutecare-hospitals-2022-update/2F824B9ADD6066B29F89C8A2A127A9DC)
)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABBLLLZQLZBBZ